![]() Hyperproteinemia, increased serum viscosity, and hyponatremia may occur. If renal function deteriorates, consider discontinuation. In patients at risk due to pre-existing renal insufficiency or predisposition to acute renal failure, assess renal function before initiation and throughout treatment, and use the minimum infusion rate practicable for IV administration. Ensure patients are not volume depleted prior to infusion. ![]() Renal Dysfunction/Failure: Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with IV use of IG products, especially those containing sucrose. IgA-deficient patients with antibodies to IgA are at greater risk of developing potentially severe hypersensitivity reactions, including anaphylaxis. If a hypersensitivity reaction occurs, discontinue infusion immediately and institute appropriate treatment. ![]() Hypersensitivity: Severe hypersensitivity reactions may occur, even in patients who have tolerated previous treatment with human IG. Anaphylaxis has been reported with intravenous (IV) use of GAMMAGARD LIQUID. IgA-deficient patients with antibodies to IgA and a history of hypersensitivity to human IG.History of anaphylactic or severe systemic hypersensitivity reactions to human IG.Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity. Ensure adequate hydration in patients before administration. For patients at risk of thrombosis, administer GAMMAGARD LIQUID at the minimum dose and infusion rate practicable.GAMMAGARD LIQUID does not contain sucrose. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. ![]() Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products.Thrombosis may occur in the absence of known risk factors. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur with immune globulin (IG) products, including GAMMAGARD LIQUID.WARNING: THROMBOSIS, RENAL DYSFUNCTION, and ACUTE RENAL FAILURE ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |